Maria Fardis, Chief Executive Officer at Lassen Therapeutics, shared a post on LinkedIn:
“I am excited to share the launch of AirNexis Therapeutics along with the close our $200M Series A financing. We will focus on advancing AN01, a Phase 2, potentially best-in-class PDE3/4 inhibitor for the treatment of chronic obstructive pulmonary disease.
I’m deeply grateful to our world class syndicate of biopharma investors, led by Frazier Life Sciences, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital, Enavate Sciences and others.
I’m also grateful for Haisco Pharmaceutical Group’s work to develop this incredibly exciting therapeutic candidate.
In the near term, we will be focused on surrounding this program with a team of experienced respiratory therapeutics developers so we can advance AN01 for patients in need.
More posts featuring Cancer Innovation.